Regulation of complement activation by C-reactive protein: Targeting of the inhibitory activity of C4b-binding protein

2007 ◽  
Vol 44 (1-3) ◽  
pp. 241
Author(s):  
Andreas P. Sjöberg ◽  
Leendert A. Trouw ◽  
Fabian McGrath ◽  
C. Erik Hack ◽  
Anna Blom
2006 ◽  
Vol 176 (12) ◽  
pp. 7612-7620 ◽  
Author(s):  
Andreas P. Sjöberg ◽  
Leendert A. Trouw ◽  
Fabian D. G. McGrath ◽  
C. Erik Hack ◽  
Anna M. Blom

2017 ◽  
Vol 199 (1) ◽  
pp. 292-303 ◽  
Author(s):  
Ádám I. Csincsi ◽  
Zsóka Szabó ◽  
Zsófia Bánlaki ◽  
Barbara Uzonyi ◽  
Marcell Cserhalmi ◽  
...  

1992 ◽  
Vol 175 (5) ◽  
pp. 1373-1379 ◽  
Author(s):  
H Jiang ◽  
F A Robey ◽  
H Gewurz

Studies were initiated to localize the C-reactive protein (CRP) binding site on the collagen-like region (CLR) of C1q. CRP bound preferentially to the A chain of reduced C1q, in contrast to aggregated immunoglobulin G (Agg-IgG), which reacted preferentially with the C chain. A group of C1q A chain peptides, including peptides identical to residues 81-97, 76-92, and 14-26, respectively, were synthesized from predicted binding regions. Peptide 76-92 contained two proximal lysine groups, and peptide 14-26 contained four proximal arginine groups. CRP-trimers and CRP-ligand complexes did not bind to immobilized peptide 81-97, but bound avidly to immobilized peptides 76-92 and 14-26. Agg-IgG did not bind to any of the peptides. Peptide 76-92 partially, and peptide 14-26 completely, inhibited binding of CRP to intact C1q. Peptide 14-26 also blocked C consumption initiated by CRP, but not by IgG. Replacement of the two prolines with alanines, or scrambling the order of the amino acids, resulted in loss of ability of peptide 14-26 to inhibit C1q binding and C activation by CRP, indicating a sequence specificity, and not a charge specificity alone, as the basis for the inhibitory activity of the peptide. Similar investigations with scrambled peptides showed a sequence specificity for the effects of peptide 76-92 as well. DNA and heparin inhibited binding of CRP trimers to intact C1q, as well as to each peptide 14-26 and 76-92, suggesting involvement of these regions in C1q-CLR binding reactions generally. Collectively, these data identify two cationic regions within residues 14-26 and 76-92 of the C1q A chain CLR as sites through which CRP binds and activates the classical C pathway, and suggest that these residues represent significant regions for C1q CLR binding reactions generally. To our knowledge, this represents the first delineation of sites on C1q through which binding and activation of the classical C pathway can occur.


2016 ◽  
Vol 310 (11) ◽  
pp. F1308-F1316 ◽  
Author(s):  
Joseph O'Flynn ◽  
Pieter van der Pol ◽  
Karen O. Dixon ◽  
Zoltán Prohászka ◽  
Mohamed R. Daha ◽  
...  

Previous studies have shown that complement activation on renal tubular cells is involved in the induction of interstitial fibrosis and cellular injury. Evidence suggests that the tubular cell damage is initiated by the alternative pathway (AP) of complement with properdin having an instrumental role. Properdin is a positive regulator of the AP, which can bind necrotic cells as well as viable proximal tubular epithelial cells (PTECs), inducing complement activation. Various studies have indicated that in the circulation there is an unidentified inhibitor of properdin. We investigated the ability of C-reactive protein (CRP), both in its monomeric (mCRP) and pentameric (pCRP) form, to inhibit AP activation and injury in vitro on renal tubular cells by fluorescent microscopy, ELISA, and flow cytometry. We demonstrated that preincubation of properdin with normal human serum inhibits properdin binding to viable PTECs. We identified mCRP as a factor able to bind to properdin in solution, thereby inhibiting its binding to PTECs. In contrast, pCRP exhibited no such binding and inhibitory effect. Furthermore, mCRP was able to inhibit properdin-directed C3 and C5b-9 deposition on viable PTECs. The inhibitory ability of mCRP was not unique for viable cells but also demonstrated for binding to necrotic Jurkat cells, a target for properdin binding and complement activation. In summary, mCRP is an inhibitor of properdin in both binding to necrotic cells and viable renal cells, regulating complement activation on the cell surface. We propose that mCRP limits amplification of tissue injury by controlling properdin-directed complement activation by damaged tissue and cells.


Sign in / Sign up

Export Citation Format

Share Document